The vaccine against human papillomavirus (HPV), the sexually transmitted virus that causes cervical cancer, is very cost-effective when given to girls at age 12 but a government-funded now raises questions about the value of pushing for vaccinating women ages 13 to 21.

Two researchers at the Harvard School of Public Health who did the study took into account the benefit of an intervention such as a vaccine in terms of the person's health and also the cost of the intervention to determine the cost-effectiveness

Women who suffered from preeclampsia, which produces high blood pressure during pregnancy, are at a greater risk of developing end-stage renal disease (ESRD), new studies have found.

Preeclampsia is a complication of pregnancy characterized by high blood pressure, protein in the urine, and swelling, as well as more serious problems, according to the National Institutes of Health

Odors from skin can be used to identify basal cell carcinoma, the most common form of skin cancer, a new study has found. If proven successful, it would be a fast, simple and noninvasive test to diagnose the most common form of skin cancer in the United States.

Study author Michelle Gallagher, who conducted her research while a postdoctoral fellow at the Monell Chemical Senses Center in Philadelphia, sampled air above basal cell tumors and found a different profile of chemical compounds compared to skin located at the same sites in healthy control subjects

For patients with coronary artery disease, supplementing with B vitamins and folic acid does not reduce the risk associated with it, a new study has found.

The new study, reported in the Aug. 20 issue of the Journal of the American Medical Association, analyzed almost 3,100 volunteers. Three-quarters of them took various doses of vitamin B and folic acid (which is chemically a B vitamin), while the others got a placebo, an inactive substance

Researchers said on Tuesday they have devised a way to grow large quantities of blood in the lab using human embryonic stem cells, opening the door to a potential new source of blood for donor banks.

Advanced Cell Technology Inc. scientists were able to make up to 100 billion red blood cells that would be enough to fill two or three collection tubes from a single plate of embryonic stem cells